Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.
about
Prevention of Hepatitis B reactivation in the setting of immunosuppressionRisk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients.Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
P2860
Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Lymphocyte/monocyte ratio and ...... homa and resolved hepatitis B.
@en
Lymphocyte/monocyte ratio and ...... homa and resolved hepatitis B.
@nl
type
label
Lymphocyte/monocyte ratio and ...... homa and resolved hepatitis B.
@en
Lymphocyte/monocyte ratio and ...... homa and resolved hepatitis B.
@nl
prefLabel
Lymphocyte/monocyte ratio and ...... homa and resolved hepatitis B.
@en
Lymphocyte/monocyte ratio and ...... homa and resolved hepatitis B.
@nl
P2093
P2860
P1433
P1476
Lymphocyte/monocyte ratio and ...... homa and resolved hepatitis B.
@en
P2093
Cheng-Hwai Tzeng
Chia-Jen Liu
Chia-Yun Wu
Jin-Hwang Liu
Jyh-Pyng Gau
Liang-Tsai Hsiao
Man-Hsin Hung
Po-Min Chen
Tzeon-Jye Chiou
Yi-Hsiang Huang
P2860
P304
P356
10.3109/10428194.2014.991922
P577
2014-12-02T00:00:00Z